PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) | PA 17 302

Opportunity Information: Apply for PA 17 302

PHS 2017-02 is an omnibus (multi-agency) Funding Opportunity Announcement from the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) that funds U.S. small businesses through the Small Business Innovation Research (SBIR) program using the Parent SBIR mechanisms R43 (Phase I) and R44 (Phase II). In practical terms, it is a broad entry point for small business concerns that want to propose high-impact research and development projects aligned with the public health, biomedical, regulatory, and product-development missions of NIH, CDC, and FDA components participating in the solicitation. The intent is to stimulate technological innovation by small companies and help move promising concepts toward products, platforms, or services that can address health and related societal needs.

The core eligibility requirement is that the applicant must be an eligible United States small business concern. Foreign institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible. However, the announcement notes that foreign components, as defined in the NIH Grants Policy Statement, may be permitted in some cases, which typically means limited, well-justified parts of the work can occur outside the United States if they are necessary for the project and consistent with NIH policy. The FOA is therefore primarily designed for domestic small businesses, while leaving a narrow policy-based pathway for specific foreign component arrangements when allowed.

This FOA is topic-driven in the sense that applicants are expected to respond to identified research topics and areas of interest described in the companion document referenced in the notice (PHS 2017-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). Those topics span the missions of the participating agencies and can cover a wide range of research and development activities across health, education, environment, food and nutrition, and income security/social services as reflected by the listed funding activity categories. The many CFDA numbers included in the notice indicate that awards may be made under numerous NIH and HHS program authorities, reflecting the breadth of scientific, clinical, public health, and regulatory domains potentially supported.

The funding instrument is a discretionary grant, meaning awards are made competitively and depend on the quality of applications, alignment with agency priorities, and available appropriations. The opportunity is structured under the standard SBIR phased approach. Phase I (R43) generally supports early feasibility and proof-of-concept R and D, while Phase II (R44) supports further development, refinement, and steps toward commercialization. While the posting you provided does not specify an award ceiling or the number of expected awards, SBIR grants commonly vary by project scope and agency guidelines, and applicants are typically expected to propose a project plan, milestones, and a credible pathway to commercialization or practical deployment consistent with SBIR program goals.

Administratively, the opportunity is identified as Funding Opportunity Number PA 17 302, created on 2017-06-05, with an original closing date listed as 2018-01-05 in the provided source data. The applicant type is explicitly small businesses, and the administering agency is NIH, with CDC and FDA participating as awarding components under the omnibus solicitation. Overall, the opportunity functions as a broad, government-wide style SBIR entry point for U.S. small businesses to propose innovative R and D projects that match one or more participating NIH/CDC/FDA topic areas, with the expectation that successful projects will advance from early technical feasibility toward development and eventual real-world use.

• The National Institutes of Health in the education, environment, food and nutrition, health, income security and social services sector is offering a public funding opportunity titled "PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.061, 93.068, 93.073, 93.084, 93.103, 93.113, 93.121, 93.136, 93.143, 93.172, 93.173, 93.213, 93.233, 93.242, 93.262, 93.273, 93.279, 93.286, 93.307, 93.316, 93.326, 93.350, 93.351, 93.361, 93.393, 93.394, 93.395, 93.396, 93.399, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.856, 93.859, 93.865, 93.866, 93.867, 93.879.
• This funding opportunity was created on 2017-06-05.
• Applicants must submit their applications by 2018-01-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for PA 17 302

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: